Clinical trials: Geriatric Disorders
SARS-CoV-2
Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older
This clinical study will assess the safety, reactogenicity, and immunogenicity of 2 dose levels of mRNA-1273 Severe Acute Respiratory Syndrome coronavirus (SARS-COV-2) vaccine in adults 18 years of age or older.
- Trial name
- NCT04405076
- Testing
- Biological: mRNA-1273, mRNA-1273.351
- Where
- 8 sites in United States
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19
Clinical Trial of Immunogenicity Bridging of a Recombinant New Coronavirus（COVID-19） Vaccine (CHO Cell)
Popular topic: A clinical trial comparing the immunogenicity of recombinant New Coronavirus vaccine (CHO cells) among people aged 3 to 17 and 18 to 59 years of age.
- Trial name
- NCT05109598
- Testing
- Recombinant new coronavirus vaccine (CHO cell)
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Influenza
Immunogenicity and Safety of AdimFlu-S 2011-2012 in Non-Elderly Adult and Elderly Subjects
The purpose of this study is to evaluate the antibody response to each of the three influenza vaccine strains included in the licensed seasonal flu vaccine, as measured by hemagglutination inhibition (HAI) at 21 days post…
- Trial name
- NCT01411358
- Testing
- non-elderly aged between 18 and 60, elderly aged over 60
- Where
- Taiwan
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
Schizophrenia
Safety Study With Paliperidone ER Extended-Release (ER) Tablets in Geriatric Patients With Schizophrenia
The primary objective of the study is to evaluate the safety and tolerability of flexible dosages of paliperidone ER as compared with placebo in patients with schizophrenia who are 65 years of age or older.
- Trial name
- NCT00085748
- Testing
- paliperidone ER
- Volunteers
- 114 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Influenza
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
The objective of the study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A.
- Trial name
- NCT00968526
- Testing
- GSK investigational vaccine GSK2340272A
- Where
- Belgium
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cognitive Decline, Mild Cognitive Impairment
The Effects of Chicken Extract and a Peptide Supplement for the Prevention of Cognitive Decline in Non-demented Elderly Adults
This trial investigates the effect of a chicken extract supplement and a peptide supplement on cognitive function and potential mechanisms of action of cognitive decline during ageing, among non-demented elderly adults using a…
- Conditions
- Cognitive Decline, Mild Cognitive Impairment, Aging
- Trial name
- NCT04555655
- Testing
- Chicken extract supplement, Peptide Supplement
- Where
- 3 sites in Taiwan
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- Brand's Suntory Asia
Herpes Zoster
Immunogenicity and Safety of SYS6052 in the Participants Aged 40 Years and Above
Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging.
- Trial name
- NCT07892989
- Testing
- Recombinant Zoster Vaccine (CHO cell) SYS6052, Active Comparator Vaccine
- Volunteers
- 496 people, healthy volunteers welcome
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Influenza
A Study to Evaluate Safety and Immunogenicity of FluvalAB-like Influenza Vaccine in Non-Elderly Adult and Elderly Subjects
The purpose of this study is to determine the immunogenicity and tolerability of one 0.5 mL intramuscular (IM) injection of FLUVAL AB-like trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza…
- Trial name
- NCT01459276
- Testing
- Vaccination with FAB-6011, Vaccination with FluvalAB
- Where
- 7 sites in Hungary
- Volunteers
- 1,206 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Influenza
Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly People
The purpose of the study is to evaluate the safety of GSK Biologicals' influenza vaccine. Elderly subjects were randomized in the primary study (NCT00760617) and will now receive the same vaccine for the third time.
- Trial name
- NCT00992784
- Testing
- GSK investigational vaccine 2186877A, FluarixTM
- Where
- 24 sites in Germany, Netherlands and 1 more
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Arteriosclerosis
Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)
RATIONALE: Atherothrombosis is a progressive and generalized vascular disease resulting in events leading to myocardial infarction (heart attack), stroke, and vascular death.
- Trial name
- NCT00050817
- Testing
- clopidogrel (SR25990)
- Where
- 32 sites in United States, Argentina and 30 more
- Volunteers
- 15,603 people
- Sponsor
- Sanofi
Hepatitis B
Comparison of Monodose and Multidose Presentations of GSK Biologicals' Hepatitis B Vaccine in Terms of Immune Response
GSK Biologicals' currently licensed multidose hepatitis B vaccine will be compared to the currently licensed monodose hepatitis B vaccine in a population with well documented hepatitis B immunological response to the vaccine…
- Trial name
- NCT00197158
- Testing
- Hepatitis B vaccine
- Where
- Belgium
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19, SARS-CoV-2 Infection
A Study to Evaluate the Efficacy and Safety of SCTV01E (a COVID-19 Vaccine) in Population Aged ≥18 Years
The objective of this study is to evaluate the effectiveness of SCTV01E in participants aged ≥18 years.
- Trial name
- NCT05308576
- Testing
- SCTV01E
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
COVID-19
Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine Adjuvanted With Alum+CpG 1018
The study is an observer-blind, randomized, controlled prospective intervention study of Phase I. The primary objective is to evaluate the safety and immunogenicity of the SARS-CoV-2 protein subunit recombinant vaccine adjuvanted…
- Trial name
- NCT05228613
- Testing
- SARS-CoV-2 protein subunit recombinant vaccine, SARS-CoV-2 inactivated vaccine
- Where
- 2 sites in Indonesia
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Gastroesophageal Reflux Disease
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents
The purpose of this study was to assess the safety and effectiveness of once daily oral administration of dexlansoprazole delayed-release capsules in adolescent participants with symptomatic non-erosive gastroesophageal reflux…
- Trial name
- NCT01642602
- Testing
- Dexlansoprazole
- Where
- 64 sites in United States, Belgium and 6 more
- Volunteers
- 104 people
- Sponsor
- Takeda
Alzheimer Disease, Early Onset
Ryan Companion Robot for Assisting Elderly People With Alzheimer's Disease
The objective of this project is to conduct research and a pilot study to demonstrate the potential clinical impact and technical feasibility of a socially-assistive robot, called Ryan Companionbot (hereafter Ryan), for life…
- Trial name
- NCT05052866
- Testing
- Social Robot
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- DreamFace Technologies, LLC
Wilson Disease
Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease
The study will evaluate the efficacy and safety of ALXN1840 (formerly called WTX101) administered for 48 weeks compared to standard of care (SoC) in Wilson Disease (WD) participants aged 12 and older in the Primary Evaluation…
- Trial name
- NCT03403205
- Testing
- ALXN1840, SoC Therapy
- Where
- 56 sites in United States, Australia and 20 more
- Volunteers
- 214 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Asthma
Post-marketing Safety Monitoring Program of Fluticasone Propionate (FP) in Chinese Subjects With Asthma Aged 1 to <4 Years
For the prophylactic treatment of asthma, FP inhaled aerosol (Flixotide ®) administered via a pressurized metered-dose inhaler (pMDI) was approved in China in adults, adolescents older than 16 years of age and children aged 4 to…
- Trial name
- NCT03273946
- Testing
- Fluticasone propionate
- Where
- 4 sites in China
- Volunteers
- 158 people
- Sponsor
- GlaxoSmithKline
Dravet Syndrome
Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome
The purpose of this study is to investigate the effect on the frequency of tonic-clonic and clonic seizures of clobazam as adjunctive therapy compared to placebo after 16 weeks of treatment in paediatric patients aged ≥1 to ≤16…
- Trial name
- NCT02174094
- Testing
- Clobazam
- Where
- 9 sites in United States, Mexico
- Sponsor
- H. Lundbeck A/S
Meningococcal Disease
Safety of MenACWY-CRM Vaccination in Adolescents
The purpose of this US FDA post-marketing commitment study is to evaluate the safety of MenACWY-CRM among 50.000 vaccinated adolescents within a large US Healthcare Maintenance Organization who received MenACWY-CRM vaccination as…
- Trial name
- NCT01452464
- Testing
- MenACWY-CRM
- Where
- 3 sites in United States
- Volunteers
- 55,397 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Pulmonary Arterial Hypertension
To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.
To demonstrate a dose response for 1 mg, 5 mg and 20 mg TID oral sildenafil for the treatment of subjects with PAH.
- Trial name
- NCT00430716
- Testing
- Sildenafil citrate
- Where
- 46 sites in United States, Belgium and 15 more
- Volunteers
- 130 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.